Patient handout

Cardiac tamponade — purulent bacterial pericarditis

PRODUCTION

1. Your condition

This handout is for cardiac tamponade — purulent bacterial pericarditis. Your care team identified this based on: septic-appearing patient (fever, tachycardia, hypotension) with pericardial effusion + beck triad — purulent pericarditis until proven otherwise; mortality 40-77% (esc 2015 §purulent pericarditis; pankuweit heart 2013 pmid 23257306).

Other reasons your team may use this plan: pneumonia / empyema (especially s. pneumoniae or staph) developing new pericardial effusion → contiguous spread purulent pericarditis (sagristà-sauleda ehj 2002 pmid 12122206); post-cardiothoracic surgery (cabg, valve, esophagectomy) within 30 days with new pericardial effusion + sternal wound drainage / fever / leukocytosis → mediastinitis with contiguous spread (gram-negatives + mrsa; augustin ejcts 2011); documented bacteremia (especially s. aureus) or known infective endocarditis with new pericardial effusion → hematogenous seeding (esc 2023 endocarditis pmid 37622656).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

Medication	Starting dose	How	When	What it does
vancomycin	loading 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h targeting AUC 400-600 mg·h/L	IV	q8-12h with AUC monitoring	IDSA 2024 MRSA bacteremia — first-line empiric for purulent pericarditis given S. aureus ~50% etiology; AUC-targeted dosing reduces nephrotoxicity vs trough-only
ceftriaxone	2 g IV q24h (q12h for CNS / endocarditis source overlap)	IV	q24h	ESC 2015 + Pankuweit 2013 — first-line for community-acquired purulent pericarditis covering S. pneumoniae + susceptible gram-negatives + N. meningitidis
cefepime	2 g IV q8h	IV	q8h	Anti-Pseudomonal coverage for healthcare-associated / post-cardiothoracic surgery / neutropenic patients per IDSA 2024 + Augustin EJCTS 2011
piperacillin-tazobactam	4.5 g IV q6h (extended infusion preferred)	IV	q6h extended infusion	Alternative anti-Pseudomonal + anaerobic coverage for nosocomial / post-surgical purulent pericarditis (Surviving Sepsis 2026)
metronidazole	500 mg IV q8h	IV	q8h	Anaerobic coverage for esophageal perforation / dental sepsis spread / mediastinitis (ESC 2015 §Purulent; Augustin EJCTS 2011)
linezolid	600 mg IV q12h	IV	q12h	IDSA 2024 alternative to vancomycin for MRSA when intolerance, AUC unachievable, or VRE confirmed; serotonergic + thrombocytopenia surveillance
streptokinase	250,000-500,000 U intrapericardial via catheter	intrapericardial	q24h × 3-7d via catheter	Maisch ESC 2004 + Tomkowski Cardiology 2008 — intrapericardial fibrinolytics dissolve fibrin loculations + facilitate complete drainage + reduce constriction risk
alteplase	10-25 mg intrapericardial via catheter	intrapericardial	q24h × 3-7d	tPA alternative to streptokinase for intrapericardial fibrinolysis (Tomkowski 2008); preferred if prior streptokinase exposure (allergic/antibody risk)
normal saline	30 mL/kg over first 3h if MAP <65 and lactate ≥4	IV	goal-directed bolus then reassess	Surviving Sepsis 2026 — sepsis bundle 30 mL/kg crystalloid for hypotension; CAUTIOUS in tamponade (preload-dependent but volume overload risk if RH dysfunction)
norepinephrine	0.05-0.1 µg/kg/min titrate to MAP ≥65	IV	continuous	Surviving Sepsis 2026 + ESC 2015 — first-line vasopressor for both septic and obstructive shock; bridge to drainage + source control

Plan: Purulent bacterial pericarditis — emergent surgical drainage + empiric vancomycin + ceftriaxone (expand for nosocomial / post-surgical) + intrapericardial fibrinolytics + sepsis bundle (ESC 2015; Pankuweit Heart 2013 PMID 23257306; Surviving Sepsis 2026)

3. When to call your provider

Contact your care team if any of the following happen:

Symptomatic constrictive pericarditis (NYHA II-IV with constrictive physiology on imaging) → cardiothoracic surgery for pericardiectomy (Class IIa per ESC 2015; ~25-35% develop)
Recurrent purulent effusion → emergent re-drainage + ID workup + extended antibiotics
Antibiotic-associated complications (C. diff, AKI sequelae) → targeted management
Effusive-constrictive pattern post-drainage → CMR + cardiothoracic for pericardiectomy evaluation

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

Hypotension with MAP <65 + lactate ≥4 + tamponade physiology — DUAL OBSTRUCTIVE + SEPTIC shock requiring emergent simultaneous management (Surviving Sepsis 2026; ESC 2015)(life-threatening)
Persistent loculated purulent effusion despite pericardiocentesis catheter + intrapericardial fibrinolytics × 3-5 days — surgical pericardiectomy mandatory (ESC 2015 §Purulent; Augustin EJCTS 2011)(life-threatening)
MRSA, MDR gram-negative (ESBL, CRE), or VRE confirmed on culture — empiric regimen needs expansion or substitution (IDSA 2024)
Constrictive pericarditis physiology developing during or after IV antibiotic completion — ~25-35% of purulent pericarditis develop constriction requiring pericardiectomy (ESC 2015 Class IIa; Pankuweit Heart 2013 PMID 23257306)
Hematogenous purulent pericarditis with confirmed endocarditis (TEE positive) OR contiguous spread from mediastinitis (CT confirmed) — extended antibiotics 6-8 wk + concurrent surgical management of primary source (ESC 2023 Endocarditis PMID 37622656; Augustin EJCTS 2011)

6. Sources

Guideline: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Purulent Pericarditis — remains current as of 2026-05-15. Pankuweit Heart 2013 PMID 23257306 anchors modern diagnostic + management framework; Surviving Sepsis Campaign 2026 update anchors antibiotic-within-1h + sepsis bundle + dual-shock management; IDSA 2024 MRSA bacteremia guideline anchors vancomycin AUC-targeted dosing + alternatives; Maisch ESC 2004 + Tomkowski Cardiology 2008 anchor intrapericardial fibrinolytics; Augustin EJCTS 2011 anchors surgical pericardiectomy in purulent.